Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$59.20 USD

59.20
312,253

+0.25 (0.42%)

Updated Aug 14, 2024 04:00 PM ET

After-Market: $59.32 +0.12 (0.20%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

ANI Pharmaceuticals (ANIP) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $51.30, marking a +0.33% move from the previous day.

Ensign Group (ENSG) Up 26% in a Year: More Room to Run?

by Zacks Equity Research

Ensign Group (ENSG) is well-poised for growth on the back of an aging U.S. population, an expanding healthcare portfolio and prudent deployment of capital.

GSK's (GSK) Gonorrhoea Vaccine Gets FDA Fast Track Tag

by Zacks Equity Research

The FDA grants fast-track designation to GSK's investigational gonorrhoeae vaccine candidate. The grant enables GSK to seek expedited review for a potential FDA filing of the vaccine.

Sarepta (SRPT) Gets FDA's Accelerated Nod for DMD Gene Therapy

by Zacks Equity Research

Following FDA???s approval, Sarepta's (SRPT) Elevidys becomes the first gene therapy for treating DMD.

Lilly (LLY) Gets FDA Nod for Pediatric Use of Diabetes Drugs

by Zacks Equity Research

Following FDA's label expansion approval, Lilly's (LLY) Jardiance and Synjardy are the first SGLT2 inhibitors approved for use in children aged 10 years and older with type 2 diabetes.

Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?

by Zacks Equity Research

Here is how ANI Pharmaceuticals (ANIP) and Cardiol Therapeutics Inc. (CRDL) have performed compared to their sector so far this year.

DICE Therapeutics (DICE) Up 37% on Buyout Offer from Eli Lilly

by Zacks Equity Research

DICE Therapeutics (DICE) is set to be acquired by pharma-giant Eli Lilly (LLY) in an all-cash transaction for $2.4 billion. The transaction will likely close by third-quarter 2023.

ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AstraZeneca (AZN) May Reportedly Spin-Off its Chinese Business

by Zacks Equity Research

AstraZeneca (AZN) reportedly plans to spin-off its China business and list it separately in Hong Kong to protect itself from rising tensions between the United States and China.

2seventy (TSVT) Down 9% on Patient Death in Leukemia Study

by Zacks Equity Research

Following a patient's death, investigators pause an early-stage study on 2seventy bio's (TSVT) CAR-T cell therapy in AML indication. However, it is still unclear whether the death was due to the treatment.

Humana (HUM) Wins Contract to Serve Oklahoma's Medicaid Members

by Zacks Equity Research

Humana (HUM) secures a contract from the OHCA and is likely to provide improved health outcomes for Medicaid members of Oklahoma.

Is Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Bellerophon Therapeutics (BLPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study

by Zacks Equity Research

A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.

Tenet Healthcare (THC) Gains 42.1% YTD: More Room to Run?

by Zacks Equity Research

Tenet Healthcare's (THC) aim to boost USPI's network through continuous buyouts is positioning the company well for growth.

Mirati's (MRTX) Sitravatinib Fails Lung Cancer Study, Stock Down 8%

by Zacks Equity Research

Mirati Therapeutics' (MRTX) phase III study evaluating sitravatinib as a combination therapy in certain NSCLC patients fails to meet its primary endpoint.

Sarepta (SRPT) Down 11% on FDA Extending DMD Gene Therapy Review

by Zacks Equity Research

The FDA extends the review period for Sarepta's (SRPT) BLA for DMD gene therapy by almost four weeks to Jun 22. The agency may limit the use of the therapy in children aged between four and five.

Factors That Make Ensign Group (ENSG) a Lucrative Bet Now

by Zacks Equity Research

Ensign Group (ENSG) is well-poised for growth on increasing service revenues, an expanding healthcare portfolio and a strong capital position.

Here's Why You Should Hold UnitedHealth Group (UNH) Stock Now

by Zacks Equity Research

Membership growth, expanding government business and improving operating margin poise UnitedHealth Group (UNH) well for growth.

PTC Therapeutics' (PTCT) Rare Disease Drug Fails in Study

by Zacks Equity Research

PTC Therapeutics' (PTCT) vatiquinone did not achieve its primary endpoint in a late-stage study in treating Friedreich Ataxia patients. Shares decline 21% post the news.

Moderna (MRNA) Posts Upbeat Data on Protein Replacement Therapy

by Zacks Equity Research

Interim data from a study shows that Moderna's (MRNA) investigational therapy for propionic acidemia (PA) exhibited early signs of dose-dependent pharmacology and potential clinical benefits.

PTC Therapeutics' (PTCT) PKU Drug Meets Study Goal, Up 7.6%

by Zacks Equity Research

Data from a late-stage study data shows that treatment with PTC Therapeutics' (PTCT) sepiapterin led to a significant reduction in Phe levels in PKU patients. Post the news, share price rises.

Immutep (IMMP) Surges 65% on Upbeat Lung Cancer Study Data

by Zacks Equity Research

A mid-stage study data shows that Immutep's (IMMP) lead candidate as a combination therapy in first-line NSCLC achieved better-than-expected overall survival results.

Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how ANI Pharmaceuticals (ANIP) and Compugen (CGEN) have performed compared to their sector so far this year.

FTC Challenges Amgen's (AMGN) $28B Acquisition of Horizon

by Zacks Equity Research

Per the FTC, Amgen's (AMGN) acquisition of Horizon (HZNP) would entrench the monopoly positions for the latter's medications for thyroid eye disease and chronic refractory gout.

HCA Healthcare (HCA) Gains 29% in a Year: More Upside Left?

by Zacks Equity Research

HCA Healthcare (HCA) is well-poised for growth on the back of higher revenues, a diversified treatment network and sound operating cash flows.